Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
OBJECTIVE: Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertensio...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3880276?pdf=render |
| _version_ | 1818047671119642624 |
|---|---|
| author | Weijie Wang Jiqi Yan Huakai Wang Minmin Shi Mingjun Zhang Weiping Yang Chenghong Peng Hongwei Li |
| author_facet | Weijie Wang Jiqi Yan Huakai Wang Minmin Shi Mingjun Zhang Weiping Yang Chenghong Peng Hongwei Li |
| author_sort | Weijie Wang |
| collection | DOAJ |
| description | OBJECTIVE: Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertension, and focuses on mammalian target of rapamycin (mTOR) pathway as a potential modulator in the early phase of cirrhotic portal hypertension. METHODS: Early cirrhotic portal hypertension was induced by bile duct ligation (BDL) for three weeks. One week after operation, sham-operated (SHAM) and BDL rats received rapamycin (2 mg/kg/day) by intraperitoneal injection for fourteen days. Vehicle-treated SHAM and BDL rats served as controls. Fibrosis, inflammation, and portal pressure were evaluated by histology, morphometry, and hemodynamics. Expressions of pro-fibrogenic and pro-inflammatory genes in liver were measured by RT-PCR; alpha smooth muscle actin (α-SMA) and antigen Ki67 were detected by immunohistochemistry; expressions of AKT/mTOR signaling molecules, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, and interleukin-1 beta (IL-1β) were assessed by western blot. RESULTS: The AKT/mTOR signaling pathway was markedly activated in the early phase of cirrhotic portal hypertension induced by BDL in rats. mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats. Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Interestingly, we also found that the level of p-ERK1/2 to ERK1/2 was significantly increased in BDL rats, which was little affected by rapamycin. CONCLUSIONS: The AKT/mTOR signaling pathway played an important role in the early phase of cirrhotic portal hypertension in rats, which could be a potential target for therapeutic intervention in the early phase of such pathophysiological progress. |
| first_indexed | 2024-12-10T10:09:29Z |
| format | Article |
| id | doaj.art-8dc6ba441b6a4c78804889f7d005cd4b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T10:09:29Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8dc6ba441b6a4c78804889f7d005cd4b2022-12-22T01:53:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8390810.1371/journal.pone.0083908Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.Weijie WangJiqi YanHuakai WangMinmin ShiMingjun ZhangWeiping YangChenghong PengHongwei LiOBJECTIVE: Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes the pathogenetic mechanisms leading to cholestatic liver fibrosis and portal hypertension, and focuses on mammalian target of rapamycin (mTOR) pathway as a potential modulator in the early phase of cirrhotic portal hypertension. METHODS: Early cirrhotic portal hypertension was induced by bile duct ligation (BDL) for three weeks. One week after operation, sham-operated (SHAM) and BDL rats received rapamycin (2 mg/kg/day) by intraperitoneal injection for fourteen days. Vehicle-treated SHAM and BDL rats served as controls. Fibrosis, inflammation, and portal pressure were evaluated by histology, morphometry, and hemodynamics. Expressions of pro-fibrogenic and pro-inflammatory genes in liver were measured by RT-PCR; alpha smooth muscle actin (α-SMA) and antigen Ki67 were detected by immunohistochemistry; expressions of AKT/mTOR signaling molecules, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, and interleukin-1 beta (IL-1β) were assessed by western blot. RESULTS: The AKT/mTOR signaling pathway was markedly activated in the early phase of cirrhotic portal hypertension induced by BDL in rats. mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure. Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats. Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin. Interestingly, we also found that the level of p-ERK1/2 to ERK1/2 was significantly increased in BDL rats, which was little affected by rapamycin. CONCLUSIONS: The AKT/mTOR signaling pathway played an important role in the early phase of cirrhotic portal hypertension in rats, which could be a potential target for therapeutic intervention in the early phase of such pathophysiological progress.http://europepmc.org/articles/PMC3880276?pdf=render |
| spellingShingle | Weijie Wang Jiqi Yan Huakai Wang Minmin Shi Mingjun Zhang Weiping Yang Chenghong Peng Hongwei Li Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. PLoS ONE |
| title | Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. |
| title_full | Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. |
| title_fullStr | Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. |
| title_full_unstemmed | Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. |
| title_short | Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. |
| title_sort | rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mtorc1 but not mtorc2 |
| url | http://europepmc.org/articles/PMC3880276?pdf=render |
| work_keys_str_mv | AT weijiewang rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT jiqiyan rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT huakaiwang rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT minminshi rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT mingjunzhang rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT weipingyang rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT chenghongpeng rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 AT hongweili rapamycinamelioratesinflammationandfibrosisintheearlyphaseofcirrhoticportalhypertensioninratsthroughinhibitionofmtorc1butnotmtorc2 |